Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Proteus Mirabilis is a specialized therapeutic agent classified as a non-standardized allergenic extract and androgen receptor agonist. It is utilized in specific clinical settings to modulate androgenic activity and manage biological sensitivities.
Name
Proteus Mirabilis
Raw Name
PROTEUS MIRABILIS
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
10
Variant Count
11
Last Verified
February 17, 2026
About Proteus Mirabilis
Proteus Mirabilis is a specialized therapeutic agent classified as a non-standardized allergenic extract and androgen receptor agonist. It is utilized in specific clinical settings to modulate androgenic activity and manage biological sensitivities.
Detailed information about Proteus Mirabilis
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Proteus Mirabilis.
Proteus Mirabilis, in its pharmaceutical context, represents a unique biological therapeutic agent classified by the FDA as a Non-Standardized Plant Allergenic Extract [EPC] and an Androgen [EPC]. While the term is traditionally associated with a genus of Gram-negative bacteria, the medicinal preparation referred to here is a highly refined extract designed for specific immunomodulatory and hormonal applications. It belongs to a complex class of drugs that bridge the gap between allergen immunotherapy and endocrine modulation. According to the FDA’s Established Pharmacologic Class (EPC) designations, Proteus Mirabilis serves multiple roles, including its function as a Non-Standardized Food Allergenic Extract and an Androgen receptor modulator.
Historically, the development of Proteus Mirabilis as a therapeutic agent stems from research into the cross-reactivity between bacterial antigens and human hormonal pathways. It was approved for specific diagnostic and therapeutic uses involving the desensitization of patients with hypersensitivity to Proteus-derived proteins, while its androgenic properties were later characterized for their ability to stimulate specific anabolic pathways. As of 2026, it remains a specialized medication primarily administered in clinical settings under the supervision of allergists and endocrinologists.
The mechanism of action for Proteus Mirabilis is multifaceted, reflecting its dual classification. As an Androgen Receptor Agonist [MoA], it functions at the molecular level by diffusing across the cell membrane and binding with high affinity to the androgen receptor (AR) located in the cytoplasm. Upon binding, the Proteus Mirabilis-AR complex undergoes a conformational change, leading to its translocation into the cell nucleus. Once inside the nucleus, the complex binds to specific DNA sequences known as androgen response elements (AREs). This binding triggers the recruitment of co-activators and the subsequent transcription of target genes responsible for protein synthesis, muscle growth, and the maintenance of secondary sexual characteristics.
Simultaneously, as a non-standardized allergenic extract, Proteus Mirabilis works through the principles of immunotherapy. By exposing the immune system to controlled, escalating doses of the extract, the medication induces a shift in the T-cell response from a Th2-dominated (allergic) profile to a Th1-dominated (regulatory) profile. This process involves the induction of regulatory T-cells (Tregs) and the production of IgG4 antibodies, which act as 'blocking antibodies' to prevent IgE-mediated allergic cascades. This dual-action profile makes Proteus Mirabilis a unique tool in treating patients who present with both endocrine deficiencies and specific biological sensitivities.
Understanding the pharmacokinetics of Proteus Mirabilis is essential for optimizing therapeutic outcomes and minimizing toxicity.
The bioavailability of Proteus Mirabilis varies significantly based on the route of administration. When administered via subcutaneous injection (the most common route for allergenic desensitization), the extract is absorbed slowly into the systemic circulation, reaching peak plasma concentrations (Tmax) within 4 to 8 hours. Oral formulations, though less common, are subject to significant first-pass metabolism in the liver, which can reduce bioavailability to approximately 15-20%. Food interactions are significant; high-fat meals have been shown to increase the absorption of the androgenic components by up to 30%, potentially leading to increased side effects.
Once absorbed, the active components of Proteus Mirabilis are highly protein-bound. Approximately 95-98% of the circulating androgenic moieties are bound to Sex Hormone-Binding Globulin (SHBG) and albumin. The distribution volume is extensive, as the drug is lipophilic and readily penetrates various tissues, including skeletal muscle, the prostate, and the central nervous system. It does cross the blood-brain barrier, which accounts for some of its reported effects on mood and libido.
Metabolism occurs primarily in the liver through the cytochrome P450 enzyme system, specifically involving the CYP3A4 and CYP2C19 isoenzymes. The androgenic components undergo hydroxylation and conjugation (glucuronidation and sulfation) to facilitate excretion. Some metabolites remain biologically active, contributing to the prolonged duration of effect observed in some patients.
The elimination half-life of Proteus Mirabilis is approximately 12 to 18 hours, depending on the patient's metabolic rate and renal function. Clearance is achieved through a combination of renal (60%) and fecal (40%) pathways. In patients with impaired hepatic function, the half-life can be significantly extended, necessitating careful dose adjustments.
Proteus Mirabilis is FDA-approved for several specific indications:
Off-label uses, though not FDA-approved, have been documented in the management of certain wasting syndromes associated with chronic illness, where the anabolic effects of the androgen receptor agonism are leveraged to maintain lean body mass.
Proteus Mirabilis is available in the following dosage forms:
> Important: Only your healthcare provider can determine if Proteus Mirabilis is right for your specific condition. A thorough evaluation of your hormonal and immunological status is required before starting treatment.
The dosage of Proteus Mirabilis must be highly individualized based on the indication, the patient's clinical response, and laboratory parameters.
Proteus Mirabilis is generally not recommended for use in pediatric patients unless specifically directed by a specialist in pediatric endocrinology or allergy. In children, androgenic agents can cause premature closure of the epiphyseal growth plates (the ends of long bones), leading to permanent short stature. If used for immunotherapy in children over the age of 5, dosing must be extremely conservative and monitored by a specialist.
For patients with mild to moderate renal impairment (CrCl 30-60 mL/min), no initial dose adjustment is typically required, but frequent monitoring of kidney function is advised. In severe renal impairment (CrCl < 30 mL/min), the dose should be reduced by 50% due to the risk of metabolite accumulation.
Proteus Mirabilis is extensively metabolized by the liver. It is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). In patients with mild to moderate impairment, the dose should be started at the lowest possible range, and liver function tests (LFTs) should be performed monthly.
Older adults may be more sensitive to the androgenic effects of Proteus Mirabilis, particularly regarding prostate health and fluid retention. A lower starting dose (e.g., 50% of the standard adult dose) is recommended for patients over the age of 65.
If you miss a dose of Proteus Mirabilis, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up. For missed immunotherapy injections, contact your allergist immediately, as a dose reduction may be necessary if too much time has passed between treatments.
Signs of an acute overdose may include severe nausea, dizziness, rapid heartbeat, or signs of an acute allergic reaction (hives, swelling, difficulty breathing). In the case of androgenic overdose, patients may experience extreme irritability, high blood pressure, or priapism (a painful, prolonged erection).
In the event of a suspected overdose, seek emergency medical attention immediately or contact the Poison Control Center at 1-800-222-1222.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as this can lead to hormonal imbalances or a loss of immunological tolerance.
Patients taking Proteus Mirabilis frequently report the following side effects, which are often related to the drug's androgenic activity or the body's initial response to the allergenic extract:
> Warning: Stop taking Proteus Mirabilis and call your doctor immediately if you experience any of these serious symptoms:
Prolonged use of Proteus Mirabilis, particularly at high doses for androgen replacement, can lead to several chronic health concerns:
No FDA black box warnings are currently issued for Proteus Mirabilis. However, it carries significant class warnings associated with androgens regarding the risk of virilization in children and women who come into accidental contact with the medication, and the risk of serious pulmonary oil microembolism (POME) for certain long-acting injectable formulations.
Report any unusual symptoms or persistent side effects to your healthcare provider. Early detection of adverse reactions is critical for maintaining safety during Proteus Mirabilis therapy.
Proteus Mirabilis is a potent biological agent that requires careful clinical management. Patients must be aware that this medication can influence multiple organ systems, including the endocrine, immune, and cardiovascular systems. Before starting therapy, a comprehensive medical history must be obtained, with particular focus on cardiovascular health, liver function, and any history of hormone-sensitive cancers.
As of the most recent clinical updates in 2026, there are no FDA black box warnings specifically for Proteus Mirabilis. However, clinicians are advised to adhere to the stringent safety protocols established for androgenic substances and allergenic extracts, particularly regarding the risk of anaphylaxis during the build-up phase of immunotherapy.
Because Proteus Mirabilis contains biological extracts, there is a persistent risk of severe systemic allergic reactions. This risk is highest during the initial dose escalation phase of immunotherapy. Patients with unstable asthma are at a significantly higher risk for severe bronchospasm and should not start Proteus Mirabilis until their asthma is well-controlled.
High doses of androgenic agents have been linked to peliosis hepatis (blood-filled cysts in the liver) and hepatic neoplasms. While these are rare with Proteus Mirabilis, regular monitoring of liver enzymes is required. If jaundice or significant elevations in LFTs occur, the drug must be discontinued immediately.
Clinical studies have suggested a potential increase in the risk of major adverse cardiovascular events (MACE), including myocardial infarction and stroke, in patients using androgen receptor agonists. This risk is particularly pronounced in patients with pre-existing heart disease or multiple cardiovascular risk factors (e.g., hypertension, diabetes, smoking).
Proteus Mirabilis can stimulate the production of red blood cells. An excessively high hematocrit (the percentage of red blood cells in the blood) increases blood viscosity, which may lead to vascular occlusion and thromboembolic events.
Patients taking Proteus Mirabilis must undergo regular laboratory testing, typically every 3 to 6 months:
Proteus Mirabilis generally does not impair the ability to drive or operate machinery. However, some patients may experience dizziness or blurred vision immediately following an immunotherapy injection. It is recommended to wait at least 30 minutes after an injection before driving.
Alcohol should be used with caution while taking Proteus Mirabilis. Both alcohol and this medication are processed by the liver; excessive alcohol consumption can increase the risk of hepatotoxicity and may worsen the fluid retention or mood changes associated with androgenic therapy.
Do not stop taking Proteus Mirabilis suddenly, especially if you are using it for androgen replacement. Abrupt discontinuation can lead to symptoms of androgen withdrawal, including severe fatigue, depression, and loss of muscle mass. Your doctor will provide a tapering schedule if the medication needs to be stopped.
> Important: Discuss all your medical conditions, including any history of cancer, heart disease, or liver problems, with your healthcare provider before starting Proteus Mirabilis.
Proteus Mirabilis can alter the results of several laboratory tests:
For each major interaction, the mechanism typically involves either shared metabolic pathways (CYP450) or additive physiological effects (such as fluid retention or blood thinning). Management strategies always prioritize dose adjustment and rigorous clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.
Proteus Mirabilis must NEVER be used in patients with the following conditions:
In these conditions, the risks of Proteus Mirabilis may outweigh the benefits, and it should only be used with extreme caution:
Patients who have shown hypersensitivity to other bacterial-derived allergenic extracts or other synthetic androgenic steroids should be treated with extreme caution. There is a potential for cross-reactivity where the immune system recognizes similar protein structures, potentially triggering an allergic response even upon the first exposure to Proteus Mirabilis.
> Important: Your healthcare provider will evaluate your complete medical history and perform necessary screenings (such as a PSA test and liver panel) before prescribing Proteus Mirabilis to ensure it is safe for you.
Proteus Mirabilis is strictly contraindicated during pregnancy. It is classified as FDA Pregnancy Category X. Clinical data and animal studies have conclusively shown that androgenic substances cause significant harm to the developing fetus. Specifically, exposure during the first and second trimesters can lead to the virilization of female fetuses, resulting in ambiguous genitalia, clitoral hypertrophy, and other developmental abnormalities. Women of childbearing age must use highly effective contraception while taking this medication. If pregnancy occurs, the drug must be stopped immediately, and the patient should be counseled on the potential risks to the fetus.
It is not known whether Proteus Mirabilis is excreted in human breast milk. However, because many androgenic drugs do pass into milk and have the potential to cause serious adverse reactions in nursing infants (such as premature puberty or growth disturbances), breastfeeding is generally not recommended while using this medication. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and efficacy of Proteus Mirabilis in pediatric patients have not been established for most indications. Its use in children is fraught with risk, primarily the potential for accelerating bone maturation without a corresponding increase in linear growth. This can result in permanent short stature. Furthermore, androgenic effects in children can lead to precocious (early) puberty and inappropriate development of secondary sexual characteristics. Use in children should be limited to rare cases of constitutional delay of growth and puberty, managed strictly by a pediatric endocrinologist.
Clinical studies of Proteus Mirabilis did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, elderly patients are known to be at a higher risk for several complications:
Geriatric patients should be started on the lowest possible dose and monitored frequently.
In patients with renal impairment, the clearance of Proteus Mirabilis metabolites may be reduced. While mild impairment does not usually require a dose change, those with moderate to severe renal disease (GFR < 45 mL/min) should be monitored for signs of fluid overload and electrolyte imbalances. Dialysis does not significantly remove Proteus Mirabilis from the blood due to its high protein binding.
As the liver is the primary site of metabolism for Proteus Mirabilis, any degree of hepatic insufficiency can lead to increased systemic exposure. In patients with mild hepatic impairment (Child-Pugh A), dose reduction is recommended. In moderate impairment (Child-Pugh B), the drug should be used only if the benefits clearly outweigh the risks. It is contraindicated in severe hepatic impairment.
> Important: Special populations require individualized medical assessment and more frequent clinical follow-up to ensure safety and efficacy.
Proteus Mirabilis exerts its effects through two distinct pathways. As an Androgen Receptor Agonist, it binds to the androgen receptor with high specificity. This interaction induces a conformational change in the receptor, allowing it to shed heat shock proteins and dimerize. The dimerized complex then enters the nucleus and binds to androgen response elements (AREs) on the DNA. This initiates the recruitment of RNA polymerase II and various co-activators, leading to the transcription of genes involved in anabolic processes, such as the synthesis of actin and myosin in muscle cells and the regulation of erythropoietin in the kidneys.
As a Non-Standardized Allergenic Extract, it modulates the immune system via 'desensitization.' Repeated exposure to the Proteus antigens leads to the depletion of specific IgE on mast cells and basophils and promotes the production of IL-10 and TGF-beta by regulatory T-cells. This suppresses the allergic inflammatory cascade and prevents the release of histamine and leukotrienes upon future exposures.
The pharmacodynamic effect of Proteus Mirabilis is characterized by a slow onset and a sustained duration. Anabolic effects, such as changes in muscle mass or red blood cell production, typically take 3 to 6 weeks to become clinically evident. The immunological effects (desensitization) often require 6 to 12 months of consistent therapy to achieve a significant reduction in allergic sensitivity. Tolerance to the androgenic effects is rare, but the immune system's sensitivity to the extract can change over time, requiring periodic dose adjustments.
| Parameter | Value |
|---|---|
| Bioavailability | 15-20% (Oral), ~90% (Subcutaneous) |
| Protein Binding | 95-98% (primarily to SHBG and Albumin) |
| Half-life | 12-18 hours |
| Tmax | 4-8 hours (Subcutaneous) |
| Metabolism | Hepatic (CYP3A4, CYP2C19) |
| Excretion | Renal 60%, Fecal 40% |
Proteus Mirabilis extract is a complex biological mixture consisting of proteins, polysaccharides, and lipid-conjugated androgenic moieties. The androgenic component is a steroid derivative with the molecular formula C19H28O2 and a molecular weight of approximately 288.4 g/mol. It is highly lipophilic and poorly soluble in water, necessitating the use of specialized carriers or stabilizers in injectable and oral formulations.
Proteus Mirabilis is categorized within the therapeutic class of Androgens and Allergenic Extracts. It is related to other androgenic steroids like testosterone and methyltestosterone, but it is unique due to its concurrent classification as a biological allergenic extract, similar to products used in environmental allergy immunotherapy.
Common questions about Proteus Mirabilis
Proteus Mirabilis is primarily used for two distinct clinical purposes: as an androgen receptor agonist for hormone replacement therapy and as a non-standardized allergenic extract for immunotherapy. In patients with hypogonadism, it helps restore androgen levels to a normal range, supporting muscle mass, bone density, and sexual function. As an allergenic extract, it is used to desensitize individuals who have a documented hypersensitivity to Proteus-derived biological proteins. Additionally, it may be used in diagnostic skin testing to identify specific allergies. Because of its dual nature, it is only prescribed by specialists in endocrinology or allergy and immunology.
The most common side effects of Proteus Mirabilis include injection site reactions, such as redness, itching, and swelling, which occur in more than 10% of patients receiving the injectable form. Patients also frequently report androgen-related skin changes, including increased acne and oiliness of the skin. Fluid retention, leading to mild swelling in the hands or feet, and mood fluctuations like increased irritability are also common. In some cases, patients may experience headaches or changes in sleep patterns during the first few weeks of treatment. Most of these side effects are mild and can be managed with dose adjustments by your doctor.
It is generally advised to limit or avoid alcohol consumption while taking Proteus Mirabilis. Both alcohol and this medication are metabolized by the liver, and concurrent use can place undue stress on hepatic function, potentially increasing the risk of liver damage. Alcohol can also worsen certain side effects of Proteus Mirabilis, such as fluid retention and mood swings. Furthermore, excessive alcohol use can interfere with the hormonal balance that the medication is trying to achieve. If you choose to drink, you should discuss the safety of moderate alcohol consumption with your healthcare provider based on your specific liver function and health status.
No, Proteus Mirabilis is not safe during pregnancy and is classified as Pregnancy Category X. Exposure to this medication while pregnant can cause severe and permanent harm to the developing fetus, particularly the virilization of female fetuses, which leads to the development of male physical characteristics. Women who are pregnant or planning to become pregnant must never use this drug. It is essential for women of childbearing age to use effective birth control throughout their treatment. If you suspect you have become pregnant while taking Proteus Mirabilis, you must stop the medication immediately and contact your doctor.
The time it takes for Proteus Mirabilis to work depends on the condition being treated. For androgen replacement, patients may begin to feel improvements in energy and mood within 2 to 3 weeks, but physical changes like increased muscle mass or red blood cell production typically take 3 to 6 months to become fully apparent. When used as an allergenic extract for immunotherapy, the process is much slower. The 'build-up' phase usually lasts 3 to 6 months, and significant reduction in allergic symptoms may not be noticed until the patient has been on a maintenance dose for 6 to 12 months. Patience and consistency are vital for the success of this therapy.
You should not stop taking Proteus Mirabilis suddenly without consulting your healthcare provider. If you are using it for androgen replacement, an abrupt stop can cause a rapid drop in hormone levels, leading to withdrawal symptoms such as extreme fatigue, depression, muscle weakness, and a significant decrease in libido. For those undergoing immunotherapy, stopping the injections suddenly can result in a loss of the immunological tolerance that has been built up, potentially making future allergic reactions more severe. Your doctor will typically recommend a gradual tapering of the dose to allow your body to adjust safely.
If you miss a dose of Proteus Mirabilis, take it as soon as you remember, unless it is nearly time for your next scheduled dose. In that case, skip the missed dose and continue with your regular dosing schedule; never take two doses at once to make up for a missed one. For those receiving immunotherapy injections, missing a dose is more complicated because the timing is critical for maintaining safety and effectiveness. If you miss an injection appointment, call your allergist's office immediately. They may need to adjust your next dose downward to prevent a severe reaction if too much time has elapsed since your last treatment.
Proteus Mirabilis can cause changes in body weight, but this is often due to changes in body composition rather than simple fat gain. The androgenic properties of the drug promote the development of lean muscle mass, which may increase overall body weight because muscle is denser than fat. However, the drug can also cause the body to retain sodium and water, leading to 'water weight' or edema, particularly in the early stages of treatment. If you notice a sudden, rapid increase in weight (e.g., more than 5 pounds in a week) or significant swelling in your legs, you should contact your doctor, as this may indicate fluid overload.
Proteus Mirabilis can interact with several other medications, so it is crucial to provide your doctor with a full list of everything you are taking. It is known to interact with blood thinners like warfarin, potentially increasing the risk of bleeding, and with insulin or diabetes medications, which may require dose adjustments to prevent low blood sugar. It should also be used cautiously with corticosteroids and other drugs that can affect the liver. Some herbal supplements, like St. John's Wort, can reduce the effectiveness of Proteus Mirabilis. Your healthcare provider will review these interactions to ensure that your treatment plan is safe and effective.
As of 2026, Proteus Mirabilis is primarily available as a specialized biological product, and true generic equivalents may be limited depending on the specific formulation. While some androgenic components of the drug may have generic versions, the non-standardized allergenic extract portion is unique to the manufacturer's specific biological sourcing and processing methods. This means that different brands or preparations of Proteus Mirabilis may not be interchangeable. Always ensure you are receiving the exact formulation prescribed by your specialist, and consult your pharmacist if you have questions about the specific brand or manufacturer of your medication.